246 related articles for article (PubMed ID: 36145321)
1. Novel and Promising Strategies for Therapy of Post-Transplant Chronic GVHD.
Kostareva I; Kirgizov K; Machneva E; Ustyuzhanina N; Nifantiev N; Skvortsova Y; Shubina I; Reshetnikova V; Valiev T; Varfolomeeva S; Kiselevskiy M
Pharmaceuticals (Basel); 2022 Sep; 15(9):. PubMed ID: 36145321
[TBL] [Abstract][Full Text] [Related]
2. Extracorporeal photophoresis: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(6):1-82. PubMed ID: 23074497
[TBL] [Abstract][Full Text] [Related]
3. Evolving Therapeutic Options for Chronic Graft-versus-Host Disease.
Gonzalez RM; Pidala J
Pharmacotherapy; 2020 Aug; 40(8):756-772. PubMed ID: 32441379
[TBL] [Abstract][Full Text] [Related]
4. Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors.
Carnevale-Schianca F; Caravelli D; Gallo S; Coha V; D'Ambrosio L; Vassallo E; Fizzotti M; Nesi F; Gioeni L; Berger M; Polo A; Gammaitoni L; Becco P; Giraudo L; Mangioni M; Sangiolo D; Grignani G; Rota-Scalabrini D; Sottile A; Fagioli F; Aglietta M
Biol Blood Marrow Transplant; 2017 Mar; 23(3):459-466. PubMed ID: 28039079
[TBL] [Abstract][Full Text] [Related]
5. Extracorporeal photopheresis in the management of graft-versus-host disease.
Bredeson C; Rumble RB; Varela NP; Kuruvilla J; Kouroukis CT;
Curr Oncol; 2014 Apr; 21(2):e310-25. PubMed ID: 24764713
[TBL] [Abstract][Full Text] [Related]
6. Novel targets in the treatment of chronic graft-versus-host disease.
Im A; Hakim FT; Pavletic SZ
Leukemia; 2017 Mar; 31(3):543-554. PubMed ID: 27899803
[TBL] [Abstract][Full Text] [Related]
7. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
8. New and emerging therapies for acute and chronic graft
Hill L; Alousi A; Kebriaei P; Mehta R; Rezvani K; Shpall E
Ther Adv Hematol; 2018 Jan; 9(1):21-46. PubMed ID: 29317998
[TBL] [Abstract][Full Text] [Related]
9. Healthcare resource utilization and costs among patients with steroid-resistant chronic graft-versus-host disease in the United States: a retrospective claims database analysis.
Yu J; Lal LS; Anderson A; DuCharme M; Parasuraman S; Weisdorf D
Curr Med Res Opin; 2021 May; 37(5):755-759. PubMed ID: 33615925
[TBL] [Abstract][Full Text] [Related]
10. Late Gastrointestinal Complications of Allogeneic Hematopoietic Stem Cell Transplantation in Adults.
Sung AD; Hassan S; Cardona DM; Wild D; Nichols KR; Mehdikhani H; Balmadrid B; Detweiler CJ; Shealy M; Cirrincione C; Li Z; Poleski M; Dalton TE; Siamakpour-Reihani S; Chao NJ; Sullivan KM
Biol Blood Marrow Transplant; 2018 Apr; 24(4):734-740. PubMed ID: 29246821
[TBL] [Abstract][Full Text] [Related]
11. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
[TBL] [Abstract][Full Text] [Related]
12. Epidemiology and Treatment of Chronic Graft-versus-Host Disease Post-Allogeneic Hematopoietic Cell Transplantation: A US Claims Analysis.
Bachier CR; Aggarwal SK; Hennegan K; Milgroom A; Francis K; Dehipawala S; Rotta M
Transplant Cell Ther; 2021 Jun; 27(6):504.e1-504.e6. PubMed ID: 34158154
[TBL] [Abstract][Full Text] [Related]
13. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
Talmadge JE
Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
[TBL] [Abstract][Full Text] [Related]
14. Late Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation.
Arora M; Cutler CS; Jagasia MH; Pidala J; Chai X; Martin PJ; Flowers ME; Inamoto Y; Chen GL; Wood WA; Khera N; Palmer J; Duong H; Arai S; Mayer S; Pusic I; Lee SJ
Biol Blood Marrow Transplant; 2016 Mar; 22(3):449-55. PubMed ID: 26541363
[TBL] [Abstract][Full Text] [Related]
15. Acute Graft
Nassereddine S; Rafei H; Elbahesh E; Tabbara I
Anticancer Res; 2017 Apr; 37(4):1547-1555. PubMed ID: 28373413
[TBL] [Abstract][Full Text] [Related]
16. Diagnosis of acute graft-versus-host disease in the gastrointestinal tract of patients undergoing allogeneic hematopoietic stem cell transplantation. A descriptive and critical study of diagnostic tests.
Borges LR; Vilela EE; Ferrari MLA; Cunha AS; Vasconcelos AC; Torres HOG
Hematol Transfus Cell Ther; 2020; 42(3):245-251. PubMed ID: 31780391
[TBL] [Abstract][Full Text] [Related]
17. Efficiency and Toxicity of Ruxolitinib as a Salvage Treatment for Steroid-Refractory Chronic Graft-Versus-Host Disease.
Wang D; Liu Y; Lai X; Chen J; Cheng Q; Ma X; Lin Z; Wu D; Xu Y
Front Immunol; 2021; 12():673636. PubMed ID: 34276662
[TBL] [Abstract][Full Text] [Related]
18. Failure to Prevent Severe Graft-Versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide in Chronic Granulomatous Disease.
Parta M; Hilligoss D; Kelly C; Kwatemaa N; Theobald N; Zerbe CS; Holland SM; Malech HL; Kang EM
J Clin Immunol; 2020 May; 40(4):619-624. PubMed ID: 32314173
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of ruxolitinib for steroid-refractory graft-versus-host disease: Systematic review and meta-analysis of randomised and non-randomised studies.
Zhang MY; Zhao P; Zhang Y; Wang JS
PLoS One; 2022; 17(7):e0271979. PubMed ID: 35905125
[TBL] [Abstract][Full Text] [Related]
20. Chronic graft-versus-host disease: Current management paradigm and future perspectives.
Mawardi H; Hashmi SK; Elad S; Aljurf M; Treister N
Oral Dis; 2019 May; 25(4):931-948. PubMed ID: 29984442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
